ATLANTA, May 1 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) a biomaterials, medical device and tissue processing company, announced today that Harvey Morgan has been elected to the Company's Board of Directors, effective immediately. Mr. Morgan is a Managing Director at Bentley Associates L.P., an investment banking firm.
Mr. Morgan has more than 35 years of investment banking experience with significant expertise in mergers and acquisitions, strategic advisory services, private placements and underwriting in a broad group of middle market companies. Mr. Morgan also serves on the boards of publicly traded Cybex International, Inc. and Family Dollar Stores, Inc and privately held Executive Health Group, Inc. He earned a bachelor of science degree from the University of North Carolina and an M.B.A. from Harvard Business School.
"I am delighted to have Harvey join the CryoLife Board of Directors. He is an excellent addition to our Board and his extensive business and financial expertise will further support our efforts to grow the company and enhance shareholder value," said Steven G. Anderson, president and chief executive officer of CryoLife, Inc.
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.
For additional information about the company, visit CryoLife's Web site: www.cryolife.com .
SOURCE CryoLife, Inc.
